But lower rectal cancer risk, suggesting differences in microbiome activity
Antibiotic use (pills/capsules) is linked to a heightened risk of bowel (colon) cancer, but a lower risk of rectal cancer, and depends, to some extent, on the type and class of drug prescribed, suggests research published online in the journal Gut.
The findings suggest a pattern of risk that may be linked to differences in gut microbiome (bacteria) activity along the length of the bowel and reiterate the importance of judicious prescribing, say the researchers.
In 2010, patients around the world took an estimated 70 billion doses of antibiotics--equivalent to 10 doses each. Antibiotics have a strong and long lasting impact on the gut microbiome, altering the balance of helpful and harmful bacteria.
The researchers wanted to find out if this might affect bowel and rectal cancer risk, and how.
They drew on data submitted to the nationally representative Clinical Practice Research Datalink (CPRD) between 1989 and 2012.
This contains the anonymised medical records of around 11.3 million people from 674 general practices--around 7% of the UK population.
The researchers collected prescribing information for 28,930 patients diagnosed with bowel (19,726 ) and rectal (9254) cancers during an average monitoring period of 8 years, and for 137,077 patients, matched for age and sex, who didn’t develop these cancers.
Antibiotics had been prescribed to 70% (20,278) of patients with bowel and rectal cancers and to 68.5% (93,862) of those without. Nearly six out of 10 study participants had been prescribed more than one class of antibiotic.
Those with bowel cancer were more likely to have been prescribed antibiotics: 71.5% vs 69%. Exposure levels were comparable among those who developed rectal cancer (67%).
The association between bowel cancer and antibiotic use was evident among patients who had taken these drugs more than 10 years before their cancer was diagnosed.
Patients who developed bowel cancer were more likely to have been prescribed antibiotics targeting anaerobes, which don’t need oxygen, as well as those targeting aerobes, which do--than patients without cancer.
But patients with rectal cancer were less likely to have been prescribed antibiotics targeting aerobic bacteria.
Cancer site was also associated with antibiotic use. Cancer of the proximal colon--the first and middle parts of the bowel--was associated with the use of antibiotics targeting anaerobes, when compared to people without cancer.
But antibiotic use was not associated with cancer of the distal colon--the last part of the bowel.
After taking account of potentially influential factors, such as overweight, smoking, and moderate to heavy drinking, cumulative use of antibiotics for a relatively short period (16+ days) was associated with a heightened risk of bowel cancer, with the impact strongest for cancers of the proximal colon.
The reverse was true for rectal cancers, where antibiotic use exceeding 60 days was associated with a 15% lower risk compared with no use.
When the analysis was restricted to patients who had been prescribed only one class of antibiotic, as opposed to none, penicillins were consistently associated with a heightened risk of bowel cancer of the proximal colon. Ampicillin/amoxicillin was the penicillin most commonly prescribed to these patients.
By contrast, the lower risk of rectal cancer was associated with prescriptions of tetracyclines.
This is an observational study, and as such, can’t establish cause, and the researchers weren’t able to capture potentially influential lifestyle factors for all the participants, nor hospital treatment, which may have affected overall cancer risk.
Nevertheless, their findings suggest “substantial” variation in the size and pattern of antibiotic effects along the length of the bowel, they say, concluding: “Whether antibiotic exposure is causal or contributory to colon cancer risk, our results highlight the importance of judicious antibiotic use by clinicians.”
Notes for editors
Research: Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: a matched case-control study doi 10.1136/gutjnl-2019-318593
Link to AMS labelling system: https://press.psprings.co.uk/AMSlabels.pdf
Peer reviewed? Yes
Evidence type: Case-control study
Link to research: https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2019-318593
If you are a journalist needing to speak to an expert, please click here.Browse our Expert Media Panel
Latest coverage of BMJ in the national and international mediaSEE BMJ IN THE NEWS
If you are a journalist who would like to receive our press releases, please provide your details.GET THE LATEST PRESS RELEASES
Email the UK media relations team for more information.CONTACT US TODAY